Cullinan Oncology Inc. and Icahn School of Medicine at Mount Sinai entered into a collaboration agreement to develop novel small molecule immune modulators.
This exclusive option and multi-year collaboration agreement will be focused on the optimization and development of oral protein degraders targeting hematopoietic progenitor kinase 1 (HPK1), a key regulator of immune cell activation and a high-priority target in immune-oncology. The collaboration aims to accelerate the development of novel, best-in-class HPK1 degraders that stimulate robust anti-tumor immunity.
Research will be conducted by scientists at both Cullinan and Icahn Mount Sinai. Cullinan will fund the collaboration and has an exclusive option to license the intellectual property for further development and commercialization.
The Icahn Mount Sinai team will be co-led by Steven J. Burakoff, Lillian and Henry M. Stratton Professor of Cancer Medicine, dean for cancer innovation, and chief of pediatric oncology, and Jian Jin, Mount Sinai professor in therapeutics discovery and director of the Mount Sinai Center for Therapeutics Discovery.
